Antitrypsin Deficiency (AATD) Augmentation Therapy Market Rising in United States | Fortune Business Insights
The global alpha-1 antitrypsin deficiency augmentation therapy market has been boosted by recent FDA approval for Prolastin-C. According to a report published by Fortune Business Insights, titled “AATD Augmentation Therapy: Global Analysis, Insights and Forecast, 2019-2026”, the market will be valued at US$ 1959.8 Mn by the end of 2025. The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the forecast period. Fortune Business Insights expects that factors such as regulatory approvals and improvements in augmentation therapies will drive the market in this period.
Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/aatd-augmentation-therapy-market-100169
Prolastin C to Emerge as the Leading Product
Type
Prolastin C
manufactured by Grifols, S.A. is considered as the most widely used product in
augmentation therapy for AATD. In terms of value, Prolastin C accounted for
63.1% share in the market in 2018. The product is expected to maintain
dominance through the forecast period. Besides Prolastin C, there are some
other product types that have been adopted widely. The recent approval
‘Respreeza’ in Europe and Asia has fueled its demand in these regions. In 2016,
Kamada Ltd and Shire plc announced the US FDA approval of expanded label for
Glassia, making it the first self-infused treatment for adults with emphysema
due to severe AATD. Therefore, increasing regulatory approvals for various
products are likely to boost the global AATD augmentation therapy market in the
forecast period.
Market in Asia Pacific to Exhibit Highest
CAGR
Active government
participation in prevention and control of genetic disorders is boosting the
AATD augmentation therapy market in Asia-Pacific. Furthermore, improved
diagnostic techniques for critical diseases is favoring expansion of the market
in Asia-Pacific. Although Asia-Pacific exhibits highest CAGR, the AATD
augmentation therapy market in North America was valued at US$ 620.0 Mn in
2018, which was the highest among all regions. The AATD augmentation therapy
market in North America is likely to remain dominant throughout the forecast
period. North America’s dominance is attributable to the rising prevalence of
AATD disorder in the U.S. and Canada, and exceptional business strategies of
leading companies in the region. Europe is estimated to be the second most
prominent region in terms of market value in 2018.
Quick
Buy - Antitrypsin Deficiency (AATD) Augmentation Therapy Market Research
Report:
https://www.fortunebusinessinsights.com/checkout-page/100169
Grifols
SA’s AlfaCare Program Has Had a Positive Impact on the Global Market
In November 2018, Grifols Sa
introduced AlfaCare, a therapy program aimed at providing training and
counselling to patients diagnosed with AATD. Grifols stated that with AlfaCare,
it aims to encourage new habits in AATD patients and help them manage their
disease properly. Research studies have proven that a huge percentage of people
diagnosed with AATD were unaware about the symptoms, effects, and ways to treat
the disorder. AlfaCare was launched to overcome all such shortcomings and
improve the quality of patient care, thereby ascertaining reduced fatality rate
of AATD. Thus, AlfaCare has transformed AATD augmentation therapies worldwide
and is likely to boost the global AATD augmentation therapy market in the
forecast period.
Related Topics :
About Us:
Fortune Business Insights™ delivers accurate data and innovative
corporate analysis, helping organizations of all sizes make appropriate
decisions. We tailor novel solutions for our clients, assisting them to address
various challenges distinct to their businesses. Our aim is to empower them
with holistic market intelligence, providing a granular overview of the market
they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Comments
Post a Comment